Nephrology
Position Statement: Management of diabetic kidney disease.
13 Jun, 2022 | 08:09h | UTC
SGLT2 inhibitor reduces the risk of hyperkalemia in patients with heart failure.
13 Jun, 2022 | 07:52h | UTCEditorial: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure
Commentary on Twitter
More evidence that SGLT2i ⬇️ hyperK, this time in heart failure
Empagliflozin reduces:
– K>6.0: HR 0.62 95% CI 0.48–0.81
– Investigator reported hyperK or K binders, HR 0.82 95% CI 0.71-0.95
– Effect modified by GFR – larger in CKD
– Regardless of MRAshttps://t.co/t4T7II1G8p pic.twitter.com/RP1EUKXHyV— Brendon Neuen (@brendonneuen) June 12, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Association of estimated GFR calculated using race-free equations with kidney failure and mortality by black vs non-black race.
8 Jun, 2022 | 11:12h | UTCEditorial: Race-Free Estimation of Kidney Function: Clearing the Path Toward Kidney Health Equity
Landmark articles suggest eliminating race in the estimation of kidney function.
Expert panel recommends against use of race in assessment of kidney function – STAT
M-A: Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease.
7 Jun, 2022 | 11:25h | UTC
RCT: Effect of perioperative dexmedetomidine on delayed graft function following a donation-after-cardiac-death kidney transplant.
7 Jun, 2022 | 10:55h | UTC
Commentary on Twitter
In this RCT, 24-hour dexmedetomidine infusion, started immediately after induction of & in addition to standard anesthesia, reduced the incidence of delayed graft function vs placebo, following a donation-after-cardiac-death kidney transplantation. https://t.co/cmX1IEZdVX
— JAMA Network Open (@JAMANetworkOpen) June 3, 2022
Guideline: Evaluation and medical management of the kidney stone patient.
2 Jun, 2022 | 11:02h | UTC
Understanding base excess (BE): merits and pitfalls.
1 Jun, 2022 | 11:33h | UTCUnderstanding base excess (BE): merits and pitfalls – Intensive Care Medicine (if the link is paywalled, try this one)
Commentary on Twitter
Understanding base excess
🧪 valuable quantitative estimate of metabolic acid-base derangements, but not info on underlying mechanisms
🧪 standard BE composite marker: several components contribute; interpretation of isolated value very difficult#FOAMcc
🖇️https://t.co/T8pcVRrTgR pic.twitter.com/6TEFsFTJR1— Intensive Care Medicine (@yourICM) May 31, 2022
Cohort Study: Intraoperative hypotension is associated with persistent acute kidney disease after noncardiac surgery.
1 Jun, 2022 | 10:53h | UTC
Cohort Study: A multisystem, cardio-renal investigation of post-COVID-19 illness.
31 May, 2022 | 11:44h | UTCA multisystem, cardio-renal investigation of post-COVID-19 illness – Nature Medicine
Commentaries:
Lingering Symptoms After COVID-19 Tied to Heart, Lung, and Kidney Injury – TCTMD
Scientists determine trajectory and pathophysiology of post-COVID-19 syndrome – News Medical
Commentary on Twitter
Deep clinical phenotyping at 28-60 days post-discharge of patients who had been hospitalized with #COVID19 and subsequent long-term follow up with electronic health records reveals evidence of persistent cardio-renal involvement. #postCOVID @ColinBerryMD https://t.co/uLxtj0b1gJ
— Nature Medicine (@NatureMedicine) May 30, 2022
M-A: Risks for donors associated with living kidney donation.
31 May, 2022 | 11:23h | UTCRisks for donors associated with living kidney donation: meta-analysis – British Journal of Surgery
Commentary from the author on Twitter (thread – click for more)
#DiversityAndInclusion 🚺🚹when counseling #Living #Kidney #Donors: our meta-analysis on the #risks stratified according to donor demographic characteristics has just been published @BJSurgery 🔗https://t.co/LtXpPeykiM @MichaelNozdrin @lisetpengel @transplantev 🧵1/7 pic.twitter.com/WszUiTAd1Q
— Maria Irene Bellini MD, PhD, FEBS, FACS (@mirenebellini1) May 26, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
M-A: Efficacy of different doses of Daprodustat for anemic non-dialysis patients with chronic kidney disease.
31 May, 2022 | 10:43h | UTCRelated Studies:
Consensus: nephrotoxic potential of 167 drugs in adult critically ill patients.
30 May, 2022 | 11:50h | UTCConsensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method – Drug Safety (if the link is paywalled, try this one)
Review: The role of peritoneal dialysis in different phases of kidney transplantation.
26 May, 2022 | 10:16h | UTCThe Role of Peritoneal Dialysis in Different Phases of Kidney Transplantation – Kidney360
Guidance on contrast associated acute kidney injury.
25 May, 2022 | 11:30h | UTCRelated:
Review: Current and emerging classes of pharmacological agents for the management of hypertension.
24 May, 2022 | 07:47h | UTCCurrent and Emerging Classes of Pharmacological Agents for the Management of Hypertension – American Journal of Cardiovascular Drugs (if the link is paywalled, try this one)
Mechanical circulatory support: primer for nephrology consultants.
24 May, 2022 | 07:38h | UTCRelated:
Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art – Critical Care
Low-flow acute kidney injury: the pathophysiology of prerenal azotemia, abdominal compartment syndrome, and obstructive uropathy.
23 May, 2022 | 00:43h | UTC
Hemoperfusion: technical aspects and state of the art.
20 May, 2022 | 10:41h | UTCHemoperfusion: technical aspects and state of the art – Critical Care
Results of two cases of pig-to-human kidney xenotransplantation.
19 May, 2022 | 11:11h | UTCResults of Two Cases of Pig-to-Human Kidney Xenotransplantation – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Genetically modified pig kidney xenografts were transplanted into two brain-dead human recipients. The xenografts functioned immediately, showed no evidence of acute rejection over a period of 54 hours. https://t.co/gWlpX1dCTC pic.twitter.com/Zp5XdA4QH5
— NEJM (@NEJM) May 18, 2022
Prescribing SGLT2 inhibitors in patients with chronic kidney disease: expanding indications and practical considerations.
19 May, 2022 | 10:43h | UTC
Commentary on Twitter
Prescribing #SGLT2 Inhibitors in Patients with #CKD : Expanding Indications and Practical Considerations
👍🏻 This interesting article discusses about practical considerations of #SGLT2i from #nephrology point of view https://t.co/Wq2plAqbhq @Nephro_Sparks @NephJC @kidney_boy pic.twitter.com/eHmpOHso86
— Henry Han (@HanCardiomd) May 17, 2022
Under a CC BY-NC-ND 4.0 license
Managing stage 1 hypertension: Consider the risks, stop the progression.
19 May, 2022 | 10:27h | UTC
RCT: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy.
18 May, 2022 | 11:20h | UTCEffect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Oral Glucocorticoids for IgA Nephropathy – JAMA
Commentary: Multi-country study provides a clear treatment option for IgA nephropathy – News Medical
Guideline of guidelines: management of recurrent urinary tract infections in women.
18 May, 2022 | 10:59h | UTC
Metabolic Alkalosis Pathogenesis, Diagnosis, and Treatment: Core Curriculum 2022.
10 May, 2022 | 11:31h | UTC
Commentary on Twitter
Metabolic Alkalosis Pathogenesis, Diagnosis, and Treatment: Core Curriculum 2022https://t.co/5ujfpBDwBz (FREE) pic.twitter.com/e1RvYVAzC8
— AJKD (@AJKDonline) May 8, 2022
RCT: Reloxaliase vs. placebo in enteric hyperoxaluria.
9 May, 2022 | 01:30h | UTCRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Commentary on Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022